WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Multiple Myeloma Clinical Trial

Official title:

A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01827137
• Other study ID #: 12-288
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 2013
• Est. completion date: August 2020

Study information

• Verified date: January 2020
• Source: Sellas Life Sciences Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if the investigator can help the immune system to work against myeloma through the use/administration of a peptide vaccine (immunotherapy agent) directed against the Wilms Tumor 1 (WT1) protein called galinpepimut-S (or GPS, for brief). Because cancer is produced by the patient's own body, the immune system does not easily recognize and fight cancer cells. The immune system needs to be "trained" to do this; the latter goal is accomplished by using a vaccine consisting of selected fragments of the target antigen, in this case, WT1.

This disease has been selected for this study because the WT1 protein is often present in myeloma cells. WT1 is a gene that is involved in the normal development of kidneys and other organs. When the WT1 gene becomes abnormal, it can make proteins involved in the development of cancer, i.e., can acquire the properties of a true "oncogene". This study will determine whether the vaccine against the WT1 antigen (present in malignant plasmacytes) can cause an immune response which is safe, but also able to keep the myeloma from either coming back or progressing.

Description:

Key Features:

• This is a Phase 1/2 clinical study conducted in patients with newly diagnosed high-risk multiple myeloma to examine the effects of GPS immunotherapy on clinical and immunobiological indices. The study is titled "A Pilot Trial of a WT1 Analog Peptide Vaccine (Galinpepimut-S) in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation" and is designed as a single-arm, single-institution, open-label study.

Rationale:

• Overexpression of WT1 in multiple myeloma (MM) cells has been demonstrated by immunocytochemistry (IHC) and in HLA-A*0201 patients by staining with a high-affinity fully human IgG1 mAb (ESK1) specific to the RMFPNAPYL/HLA-A*0201 complex on malignant plasma cells. WT1 also serves as a target for antigen-specific directly immunizing immunotherapeutic approaches, such as peptide vaccines (in this case, galinpepimut-S), in patients with multiple myeloma. Patients with persistent plasma cell leukemia following CD34+-selected allografts treated with adoptive transfer of donor-derived WT1-specific cytotoxic T cells are capable of achieving long-lasting complete remission (CR) status, thus underscoring the therapeutic potential of activated T-cells specifically immunized against WT1 peptides. The above provide the theoretical basis for the possibility of successful immunization after exposure to a WT1-specific vaccine (such as galinpepimut-S), whereby WT1-sensitized T-lymphocytes (both CD8+ and CD4+) from vaccinated MM could be directed to antigen (WT1) expressed on malignant plasma cells.

Galinpepimut-S (GPS) - Key features:

• GPS is a tetravalent peptide vaccine, consisting of an equiweight mixture of 4 WT1-derived peptides which have been chosen to strengthen antigenicity, but also broaden immunogenicity over a wide range of HLA subtypes, being able to stimulate both CD8+ (MHC Class I)- and CD4+ (MHC Class II)-dependent responses. Of note, 2 of the 4 peptides are heteroclitic, i.e., carry by-design introduced missense mutations, in order to decrease tolerogenicity (as these modified peptides are no longer identified as "self" moieties by the vaccinated host's immune system. GPS contains one heteroclitic peptide (WT1-A1) to stimulate CD8+ responses, two longer native peptides (427 long and 331 long) to stimulate CD4+ responses and one longer heteroclitic peptide (122A1 long) that is capable of stimulating both CD8+ and CD4+ cells (with the CD8-activating shorter sequence/locus 'buried' with the lengthier CD4-activating one). Galinpepimut-S is always mixed in emulsion with the immunological adjuvant Montanide™ and is administered after granulocyte-macrophage colony-stimulating factor (GM-CSF; sargramostine; Leukine®) pre-stimulation.

Putative Mechanism of action (MOA) of galinpepimut-S in MM:

• Galinpepimut-S (GPS) is a peptide immunogen of the vaccine type, capable of inducing in the treated host WT1-specific antigenicity and eventual systemic immunogenicity against WT1-expressing deposits of cancerous cells. The above principles are applicable in MM patients treated with this immunotherapeutic. It is very likely that the antigen presenting cell (APC)-CD8-CD4 cross-activating circuits are markedly amplified in subjects receiving galinpepimut-S, leading to specific and direct immunization against WT1 and eventual killing of WT1-expressing malignant plasma cells via activated immunocytes (mainly lymphocytes and natural killer [NK] cells). This MOA represents a plausible model for the immunobiological basis of the observed clinical activity of galinpepimut-S against various tumor types (other than MM) tested to-date, and is poised to be applicable in MM as well.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 22
• Est. completion date: August 2020
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Symptomatic multiple myeloma, ISS stage 1-3 with confirmed diagnosis of multiple myeloma at MSKCC

• Patients must be eligible to undergo autologous stem cell transplantation by standard institutional criteria

• Patients must have documented WT1 positive disease. For purpose of this study, this is defined as detectable presence of WT1 expression by immunohistochemistry or by WT1 transcript via RT-PCR on a bone marrow or other plasma cell-related biopsy specimen prior to autologous stem cell transplantation. Bone marrow or other biopsy specimen from time of diagnosis from patients diagnosed at MSKCC or outside hospital may be requested for assessment of WT1 expression by IHC

• Age > or = to 18 years

• Karnofsky performance status > or = to 50%

• Hematologic parameters:

• Absolute neutrophil count (ANC) > or = to 1,000/µl

• Platelets > 50,000/µl

• Biochemical parameters:

• Total bilirubin < than or = to 2.0 mg/dl

• AST and ALT < than or = to 2.5 x upper limits of normal (ULN)

• Creatinine < than or = to 2.0 mg/dl

Exclusion Criteria:

• Pregnant or lactating women

• Patients with active infection requiring systemic antimicrobials

• Patients taking systemic corticosteroids

• Patients with serious unstable medical illness

• Concurrent malignancies

Related Conditions & MeSH terms

• High-Risk Cancer
• Minimal Residual Disease
• Multiple Myeloma
• Neoplasm, Residual
• Neoplasms, Plasma Cell

Intervention

Biological:
• WT1 Analog Peptide Vaccine
Preparation of a suspension of liquid vaccine drug product preparation (100 mcg of each peptide x 4 WT1 peptides within the GPS mixture; total weight: 400 mcg) 1:1 v/v with Montanide (oil depot emulsifier) to a total volume of ~1 ml, which is then injected s.c. to the patient. GPS is administered subcutaneously with Montanide adjuvant, with the first dose within 22 days of ASCT with melphalan conditioning (200 mg/sq.m.) and biweekly administration thereafter, for a total of 6 initial doses. Subsequently, patients continued to receive booster GPS administrations every 4 weeks, for an additional set of 6 doses, assuming they remain non-progressors per International Myeloma Working Group (IMW) criteria and are also clinically stable.
• Sargramostim (GM-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine®) is administered s.c. at a dose of 70 µg on day -2 and day 0 of each GPS administration.

Drug:
• lenalidomide
IMiD (lenalidomide; 10 mg p.o. daily) OR -in select patients- proteasome inhibitor (bortezomib; 1.3 mg/sq.m. s.c. every 2 weeks) maintenance starting 3-months post auto SCT.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Sellas Life Sciences Group

Country where clinical trial is conducted

United States, 

References & Publications (1)

Koehne G, Devlin S, Korde N, Mailankody S, Landau H, Hassoun H, Lesokhin A, Lendvai N, Chung D, Sarlis N, Giralt S, Landgren O. Galinpepimut-S, a WT1-Targeting Immuno-Oncology Treatment, Induces Specific, Robust and Durable Immune Responses (IRs) in Patie

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antigen-specific T-cell immune response (IR) - early	The level of induction of T-cell (CD4+ and CD8+) immune responses against WT1 peptides within the galinpepimut-S vaccine mixture - as compared to baseline (t=0; before vaccine administration)- will be measured by intracellular interferon-? production assay and MHC tetramer analyses - the latter, if available for patient's HLA-type.	12 weeks after the initial GPS vaccine (end of first series [GPS x 6 administrations])
Primary	Antigen-specific T-cell immune response (IR) - late	The level of induction of T-cell (CD4+ and CD8+) immune responses against WT1 peptides within the galinpepimut-S vaccine mixture - as compared to baseline (t=0; before vaccine administration) - will be measured by intracellular interferon-? production assay and MHC tetramer analyses - the latter, if available for patient's HLA-type.	38 weeks after the initial GPS vaccine (end of booster series [GPS x 12 administrations])
Secondary	Progression-free survival (PFS)	From time of registration to the time of documented myeloma progression (as defined by the International Myeloma Working Group [IMW] consensus criteria; Kumar S et al. Lancet Oncol. 2016) or subject death.	2 years
Secondary	Overall survival (OS)	From time of registration to the time of subject death.	2 years
Secondary	Toxicity profile	Toxicity will be graded in accordance with Common Toxicity Criteria, version 4.0 (CTCAE 4.0) The only toxicities captured outside of the SAEs reported will be all Grade 1-5 toxicities deemed definitely, probably, or possibly related to the portion of the study. relevant to the active administration of galinpepimut-S.	2 years
Secondary	WT1 expression level quantification	Protein expression analysis for WT antigens will be done by immunohistochemistry (IHC) as follows: Monoclonal antibodies to CD138/Syndecan, co-express WT1 when staining WT1 mAB 6F-H2 will employed by the study specified research lab on MSKCC S-631.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center